Group 1: Company Overview - Dong-E E-Jiao Co., Ltd. held an investor relations activity on August 16, 2016, to discuss the company's operational status and financial indicators for the first half of 2016 [2][4]. - The meeting was attended by various institutional investors, including Huabao Investment Co., Ltd. and Goldman Sachs (Asia) LLC [2][4]. Group 2: Product Sales Performance - The sales of E-Jiao blocks remained stable during the adjustment period, focusing on cultural marketing and expanding consumer demographics [4][5]. - The Compound E-Jiao Syrup, as the longest-standing oral liquid product in China, has a solid market foundation and is being repositioned to enhance its competitiveness through marketing strategies [5][6]. - The Peach Blossom Princess E-Jiao Cake is targeting key markets in Shandong and Beijing, with innovations like the Peach Blossom Princess Year Card to boost sales [5][6]. Group 3: Raw Material Supply Chain - The domestic donkey resource is declining due to urbanization and agricultural mechanization, prompting the company to implement a full industry chain development strategy [5][6]. - The company is actively seeking government support to address funding, breeding, and sales issues for donkey farming, aiming to enhance the profitability of farmers [6]. Group 4: Financial Performance Insights - The decrease in operating cash flow is attributed to an increase in bank acceptance bills for sales collections, while cash outflows rose due to higher raw material reserve payments [6]. - The increase in inventory is mainly due to strategic reserves of raw materials [6]. - Accounts receivable and notes receivable grew due to annual credit assessments for sales customers, with a unified recovery at year-end [6].

Group 1: Marketing and Product Development - The company is focusing on modernizing its marketing strategies to adapt to changes in consumer purchasing channels, emphasizing the importance of innovation and new product development centered around traditional Chinese medicine [2][3] - The company aims to develop "Ajiao+" products to better serve consumers and expand its market reach [3] - The company is committed to enhancing research and development, including clinical studies to validate product efficacy, with projects like the integration of one million cases of compound Ajiao syrup [4] Group 2: Pricing and Market Strategy - The pricing of Ajiao products is expected to remain stable this year, but adjustments will depend on market conditions and external factors [3] - The company recognizes that Ajiao's daily consumption price is lower than other health products like cordyceps and bird's nest, which may influence pricing strategies [3] - The pricing strategy will consider market factors, product characteristics, and the scarcity of raw materials [4] Group 3: Research and Development Focus - The company is advancing in both consumer-oriented and clinical research, focusing on new product development and pharmacological validation [4] - Research efforts include improving product standards, production processes, and quality enhancement [4] - The company is exploring the potential of synthetic alternatives for Ajiao, although current capabilities are limited [4] Group 4: Industry Standards and Legal Protection - The company is actively working to combat counterfeit products through legal means and by promoting industry standards [5] - There is a belief that establishing industry standards will help regulate the market and support the company's growth [5] Group 5: Future Directions - The company is considering the integration of biological drugs into its product line, with a 49% stake in a new venture to enhance product offerings and market presence [5] - The focus will be on leveraging international platforms for broader market access and product diversification [5]

Group 1: Company Overview - The overall business operation of Dong'e Ejiao Co., Ltd. is stable in 2018, which is a key year for the company's "13th Five-Year Plan" development [2] - The company will continue to focus on its core business of Ejiao, promoting Ejiao cultural marketing and value recovery projects [2] - The company aims to enhance the comprehensive value of donkey resources through live donkey cycle development and experiential marketing [3] Group 2: Product Development Strategy - Dong'e Ejiao is pushing for cultural marketing and value recovery, targeting high-end health supplement consumers [3] - The company is innovating its product offerings, including the introduction of compound Ejiao products aimed at dual nourishment of Qi and blood, breaking traditional perceptions of "medicinal" products [3] - Increased investment in research and clinical validation is planned to enhance product specifications and improve customer experience [3] Group 3: Sales Performance - The sales situation of the company's products is stable, particularly during the peak season for Ejiao supplements [3] - The 12th Ejiao Nourishing Festival was held on December 22-23, 2018, attracting medical experts to discuss the inheritance and modernization of traditional Chinese medicine [3] Group 4: Shareholder Confidence - China Resources increased its stake in Dong'e Ejiao from November 6 to 19, 2018, reflecting confidence in the company's future development and recognition of its value [4]

Group 1: Company Development Strategy - The company's "13th Five-Year" strategy focuses on the core business of Ejiao, cultivating multiple brands, and promoting cultural marketing and value return projects [1] - The strategy aims to enhance the comprehensive value through live donkey resource development and extend upstream and downstream in the industry chain [1] - The company positions Ejiao as a "national treasure for nourishment," targeting high-end consumers and developing products like compound Ejiao syrup for broad consumption [3] Group 2: Sales Performance - The company is currently operating stably and believes the Ejiao market will continue to develop positively, allowing more consumers to experience the benefits of Ejiao products [3] - E-commerce sales currently account for a small proportion, with younger consumers being the primary demographic, although online consumption among middle-aged and elderly consumers is gradually increasing [3] Group 3: Shareholding and Governance - China Resources Pharmaceutical has increased its shareholding to over 30%, reflecting confidence in the company's future development and recognition of its value [3] Group 4: Supply Chain and Pricing - The supply of donkey hides includes a certain proportion from abroad, with differences in scale and systematic breeding compared to domestic practices [4] - The company adjusts product prices based on supply and demand changes, determined by market development conditions [4] Group 5: Future Product Development - The company plans to strengthen upstream resource control and implement cultural and academic marketing, focusing on clinical validation of Ejiao products [4] - There are ongoing developments in derivative products, such as Ejiao oatmeal juice, with expectations for growth [4] Group 6: Regional Sales Focus - The company aims to develop and expand in key regions such as the Yangtze River Delta and the Pearl River Delta, where competition is relatively intense [4]

Group 1: Event Details - The event is scheduled for November 16, 2022, from 14:00 to 16:00 [1] - The event will be held online via the investor relations interactive platform provided by Shenzhen Panorama Network Co., Ltd. [1] Group 2: Participation and Communication - Company representatives, including Secretary of the Board Ms. Deng Rong and Securities Affairs Representative Mr. Fu Yan, will engage with investors online [1] - Topics for discussion include corporate governance, social responsibility, operational status, development strategy, risk prevention, and investor protection [1] Group 3: Company Commitment - The company and its board guarantee the authenticity, accuracy, and completeness of the disclosed information, ensuring no false statements or significant omissions [1]